Colin L Masters is an expert in Neurology at University of Melbourne (Australia). As of October 2026, ScienceLeadR ranks Colin L Masters in the top 1% of experts worldwide for Alzheimer Disease, Dementia and Neurocognitive Disorders. Colin L Masters has authored 1,774 publications, the most recent in 2026, and is an investigator in 6 clinical trials. SLR score: 4,756 (community average: 125). How the SLR is computed.

LeadR Profile

Colin L Masters University of Melbourne Australia
4 756 ScienceLeadR Reputation 4756
Network Map

Neurology

Subspecialties: Psychiatry - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1986 - 2026

Source: PubMed

University of Melbourne

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1774

Citations

Citations: 121 967 1st author: 52 Last author: 162 Unique author: 20


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Data‑driven cognitive composites predict Aβ‑related decline and progression to MCI: the ADOPIC study.
PMID 42860384 — dementia, alzheimer disease, cognitive dysfunction, psychometrics
Alzheimers Dement20260
Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease.
PMID 42856312 — immunization, plaque, amyloid, antibodies, alzheimer disease, tomography, positron-emission tomography, brain, pathology, biomarkers, antibodies, monoclonal, therapeutics, amyloid, tissues, immunization, passive
medRxiv20260
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
PMID 42441390 — alzheimer disease, positron-emission tomography, diagnosis, amyloid
JAMA Top journal20267
Cardiometabolic medication exposures and cognitive outcomes in Alzheimer's disease.
PMID 42735389 — dementia, alzheimer disease, aging, cognitive dysfunction, antihypertensive agents, geriatrics, metformin
Age Ageing20260
Gut Microbiome Changes in Preclinical Alzheimer's Disease.
PMID 42588092 — alzheimer disease, cognitive dysfunction, diet, food, signs and symptoms, gastrointestinal microbiome, dietary patterns
Nutrients20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2/Phase 3 2
N/A 1
Phase 1 1
Phase 2 1
Phase 3 1

By status:

Completed 4
Active not recruiting 1
Recruiting 1

By type:

Interventional 5
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 14

LeadR Networks

Main global connection map